{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:41:04Z","timestamp":1780609264538,"version":"3.54.1"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Current guidelines recommend the use of combined hormonal contraceptive pills for menstrual suppression in pediatric blood and marrow transplant (BMT) recipients but recent research reveals that provider practice varies. This study was designed to describe the current practice for managing menstrual issues, that is, menstrual suppression and uterine bleeding, in pediatric BMT patients and to better understand health care providers' practices in the use of gonadotropin\u2010releasing hormone agonists (GnRHa).<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>A cross sectional survey consisting of 53 questions was distributed via email to principal investigators in the Pediatric Blood and Marrow Transplant Consortium (PBMTC). Responses were collected using <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.surveymonkey.com\/\">www.surveymonkey.com<\/jats:ext-link>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Menstrual suppression and uterine bleeding in pediatric BMT patients are primarily managed by pediatric oncologists (97%). The most frequently reported hormonal method used for induction of therapeutic amenorrhea was GnRHa (41%). The top three reasons for choosing a method were greater likelihood of amenorrhea, concerns about side effects, and possible gonadal protection. Continuous combined hormonal contraceptive pills were the most commonly used method for the management of clinically significant uterine bleeding regardless of primary method used for menstrual suppression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite the 2002 PBMTC guidelines, wide variation in menstrual suppression management practices still exists. Our data show that use of GnRHa is more common than previously reported. Additional research is needed to develop evidence\u2010based practice guidelines in pediatric BMT patients. Pediatr Blood Cancer 2012;59:553\u2013557. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.23360","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T18:41:38Z","timestamp":1329158498000},"page":"553-557","source":"Crossref","is-referenced-by-count":17,"title":["The management of menstrual suppression and uterine bleeding: A survey of current practices in the pediatric blood and marrow transplant consortium"],"prefix":"10.1002","volume":"59","author":[{"given":"Enitan A.","family":"Adegite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Marshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina S.","family":"Sucato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830420404"},{"key":"e_1_2_6_3_2","unstructured":"Clinical Practice Guidelines. Chairman Franklin O Smith MD. Pediatric Blood & Marrow Transplant Consortium. September 2002. A copy can be obtained by contacting coauthor (RKG) at rakesh.goyal@chp.edu"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgo.2007.04.036"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.08.008"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2007.03.012"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199603)51:3<248::AID-AJH17>3.0.CO;2-C"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701187"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1182\/blood.V92.12.4568","article-title":"Norethisterone treatment, a major risk\u2010factor for veno\u2010occlusive disease in the liver after allogeneic bone marrow transplantation","volume":"92","author":"H\u00e4gglund H","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105173442007"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1542\/pir.28-5-175"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22199"},{"key":"e_1_2_6_13_2","first-page":"1","article-title":"A clinicians guide to the use of gonadotropin\u2010releasing hormone analogues in women","volume":"2","author":"Moghissi K","year":"2000","journal-title":"Medscape Gen Med"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.7.3045.bloodjournal8773045"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.02.010"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2007.12.044"},{"key":"e_1_2_6_17_2","first-page":"2395","volume-title":"Cancer\u2010principles & practice of oncology","author":"Shenns R","year":"1993"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0892"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-9-1055"},{"key":"e_1_2_6_20_2","unstructured":"Adapted from the table on approved indications for GnRH agonists by the FDA.http:\/\/wwwfdagov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm209842htmMay 2010."}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23360","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.23360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T03:19:12Z","timestamp":1696907952000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.23360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,13]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1002\/pbc.23360"],"URL":"https:\/\/doi.org\/10.1002\/pbc.23360","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,13]]}}}